



Preliminary Annual Report 2008

Doubled EBIT and 56 percent increase of net sales

- **Net sales** for the year amounted to 68.0 million SEK (43.6) and for the fourth quarter to 15.7 million SEK (13.0).
- **EBIT** for the year amounted to 10.2 million SEK (5.2) and for the fourth quarter to 2.5 million SEK (1.2).
- **Profit after tax** for the year amounted to 8.0 million SEK (24.5) and for the fourth quarter to 1.4 million SEK (19.7).
- **Earnings per share** for the year amounted to 0.85 SEK (2.62) and for the fourth quarter to 0.15 SEK (2.11).
- **Cash flow** for the year amounted to 13.9 million SEK (13.0).
- Breakthrough in USA through Next Food's and Kraft Food's launch of probiotic based products.
- Successful common cold study gives possibility for product launches within the immune area during 2009.
- New agreements in the fourth quarter through Probi's partner Institut Rosell for the sales of dietary supplements based on Probi's Lp299v in Spain and Belgium.
- Probi received a research grant in the amount of 1.8 million SEK from Vinnova for research during 2009 and onward about probiotics' positive health effects within the cardiovascular field.
- Cooperation with Dr. Oz and HealthCorps in order to increase health awareness among teenagers in USA.

CEO's comments:

"2008 became a breakthrough year for Probi. We have doubled EBIT and increased net sales by 56 percent. Additionally, we have expanded business geographically as well as product-wise. A large number of agreements within Functional Food and Dietary Supplements have been made and we count on launching our new immune product during 2009. We see a large potential in this product and it conveys the strength and width of Probi's research," says Michael Oredsson, CEO of Probi.



For further information, contact:

Michael Oredsson, CEO, Probi, phone: +46 (0)46 286 89 23 or +46 (0)707 18 89 30,
e-mail: michael.oredsson@probi.se

Distributed Jan. 28th, 2009. 8.45 (CET)

About Probi

Probi is a leading player in the field of probiotic research and development of effective and well-documented probiotics. The research areas are: stomach and gastrointestinal tracts, immune defense, metabolic disorders as well as stress and recovery. Probi's customers are leading companies within the business areas Functional Food and Dietary Supplements. The company's total operating income was 69.4 million SEK 2008, consisting mostly of royalty revenues. Probi's shares are listed on the Nordic List of the Stockholm Stock Exchange, Small Cap and has approximately 4.000 shareholders. Visit www.probi.com